Biotech startup NewLimit secured $435 million in Series C funding, reaching a $3.1 billion valuation. The capital will accelerate development of a prototype medicine designed to reprogram cellular aging in the human liver—shifting metabolic intervention from theory to clinical testing.
Series C backed by pharma and venture heavyweights
The round was led by Founders Fund, with participation from Eli Lilly Ventures, Thrive Capital, Kleiner Perkins, and Greenoaks. Founded in 2021, NewLimit previously raised $130 million in 2025. The funding provides runway to move from laboratory demonstrations to human trials.
Liver-targeted epigenetic reprogramming
NewLimit has demonstrated the ability to reverse liver cell age in controlled laboratory conditions. The approach targets epigenetic marks—cellular "software"—rather than DNA itself, aiming to restore a youthful metabolic profile without permanent genetic modification. The liver was selected for its central role in glucose regulation and nutrient processing.
The lead candidate, designated M0004, improved hepatocyte regeneration and resilience to alcohol damage in preclinical models. The company has three prototype medicines in its current pipeline, all focused on epigenetic programming.
Competitive landscape and valuation context
NewLimit's $3.1 billion valuation positions it alongside Altos Labs ($3 billion investment) and above Retro Biosciences ($1.8 billion valuation). The aggressive funding reflects investor confidence in epigenetic reprogramming as a viable healthspan strategy.
What comes next
NewLimit expects to release Phase I clinical trial data in 2027. The trial will determine whether laboratory-demonstrated liver cell reprogramming translates to measurable improvements in human liver function and metabolic resilience. Safety and stability of reprogrammed cells in living systems remain the primary validation hurdles.
Science is evolving—today's best practice may shift as early-stage clinical results emerge.
This is informational content based on published research. It is not medical advice. Consult a healthcare professional before making changes to your health regimen.
Action step: Track NewLimit's Phase I clinical trial data release in 2027 to assess whether cellular reprogramming becomes a viable tool for metabolic health.
